{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:11:47Z","timestamp":1764828707424,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Kissei Pharmaceutical Co. Ltd., the manufacturer of YS110"},{"name":"Kissei Pharmaceutical Co. Ltd"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.lungcan.2019.09.010","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T11:03:30Z","timestamp":1568631810000},"page":"64-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2950-0960","authenticated-orcid":false,"given":"Masayuki","family":"Takeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9090-801X","authenticated-orcid":false,"given":"Hidehito","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyoaki","family":"Hida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaname","family":"Nosaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikao","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lungcan.2019.09.010_bib0005","first-page":"544","article-title":"MPM: malignant pleural mesothelioma","volume":"1","author":"Cao","year":"2012","journal-title":"Ann. Cardiothorac. Surg."},{"key":"10.1016\/j.lungcan.2019.09.010_bib0010","article-title":"Prognostic factors of survival in patients with malignant pleural mesothelioma; an analysis of the National Cancer data Base","author":"van Gerwen","year":"2019","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.lungcan.2019.09.010_bib0015","first-page":"1","article-title":"Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model","volume":"49","author":"Murayama","year":"2006","journal-title":"Am. J. Ind. Med."},{"year":"2019","series-title":"NCCN Clinical Practice Guidelines in Oncology: Malignant Pleural Mesothelioma. Version 1.2019","author":"National Comprehensive Cancer Network","key":"10.1016\/j.lungcan.2019.09.010_bib0020"},{"issue":"5","key":"10.1016\/j.lungcan.2019.09.010_bib0025","first-page":"562","article-title":"Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations","volume":"7","author":"De Bondt","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"issue":"5","key":"10.1016\/j.lungcan.2019.09.010_bib0030","first-page":"574","article-title":"Current chemotherapy strategies in malignant pleural mesothelioma","volume":"7","author":"de Gooijer","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2019.09.010_bib0035","article-title":"Malignant pleural mesothelioma outcomes in the era of combined platinum and folate antimetabolite chemotherapy","volume":"2015","author":"Saint-Pierre","year":"2015","journal-title":"Lung Cancer Int."},{"key":"10.1016\/j.lungcan.2019.09.010_bib0040","first-page":"55","article-title":"The structure and function of CD26 in the T-cell immune response","volume":"161","author":"Morimoto","year":"1998","journal-title":"Immunol. Rev."},{"issue":"39","key":"10.1016\/j.lungcan.2019.09.010_bib0045","first-page":"14186","article-title":"CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1","volume":"101","author":"Ohnuma","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"10.1016\/j.lungcan.2019.09.010_bib0050","first-page":"1369","article-title":"Overexpression of CD26\/DPPIV in mesothelioma tissue and mesothelioma cell lines","volume":"26","author":"Amatya","year":"2011","journal-title":"Oncol. Rep."},{"issue":"14","key":"10.1016\/j.lungcan.2019.09.010_bib0055","first-page":"4191","article-title":"Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors","volume":"13","author":"Inamoto","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2019.09.010_bib0060","first-page":"1754","article-title":"A novel role for CD26\/dipeptidyl peptidase IV as a therapeutic target","volume":"23","author":"Ohnuma","year":"2018","journal-title":"Front. Biosci. (Landmark Ed.)"},{"issue":"7","key":"10.1016\/j.lungcan.2019.09.010_bib0065","first-page":"2031","article-title":"In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299","volume":"7","author":"Ho","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"11 Pt 1","key":"10.1016\/j.lungcan.2019.09.010_bib0070","first-page":"3470","volume":"12","author":"Inamoto","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2019.09.010_bib0075","first-page":"35","article-title":"A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2\/M cell cycle transition","volume":"16","author":"Hayashi","year":"2016","journal-title":"Cancer Cell Int."},{"issue":"9","key":"10.1016\/j.lungcan.2019.09.010_bib0080","first-page":"1126","article-title":"First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers","volume":"116","author":"Angevin","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2019.09.010_bib0085","first-page":"257","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2019.09.010_bib0090","first-page":"855","article-title":"[Development of new therapy for malignant mesothelioma based on CD26 molecule]","volume":"43","author":"Morimoto","year":"2016","journal-title":"Gan To Kagaku Ryoho"},{"issue":"1","key":"10.1016\/j.lungcan.2019.09.010_bib0095","first-page":"68","article-title":"The effects of corticosteroids on lymphocyte recirculation in humans: analysis of the mechanism of impaired lymphocyte migration to lymph node following methylprednisolone administration","volume":"43","author":"Sackstein","year":"1995","journal-title":"J. Investig. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2019.09.010_bib0100","first-page":"F661","article-title":"Diabetes, hypertension, and chronic kidney disease progression: role of DPP4","volume":"312","author":"Nistala","year":"2017","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"1","key":"10.1016\/j.lungcan.2019.09.010_bib0105","first-page":"97","article-title":"Soluble dipeptidyl Peptidase-4 levels are associated with decreased renal function in patients with type 2 diabetes mellitus","volume":"43","author":"Cho","year":"2019","journal-title":"Diabetes Metab. J."},{"issue":"5","key":"10.1016\/j.lungcan.2019.09.010_bib0110","first-page":"1447","article-title":"CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma","volume":"18","author":"Aoe","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2019.09.010_bib0115","first-page":"257","article-title":"Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth","volume":"20","author":"Hollande","year":"2019","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.lungcan.2019.09.010_bib0120","first-page":"850","article-title":"Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy","volume":"16","author":"Barreira da Silva","year":"2015","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.lungcan.2019.09.010_bib0125","first-page":"791","article-title":"DPP4 in anti-tumor immunity: going beyond the enzyme","volume":"16","author":"Ohnuma","year":"2015","journal-title":"Nat. Immunol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219306543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219306543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:29:54Z","timestamp":1759235394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500219306543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":25,"alternative-id":["S0169500219306543"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.09.010","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}